A study on prostaglandin E1 therapy in critical limb ischaemia patients to evaluate the improvement in vascularity

Authors

  • John S. Kurien Department of General Surgery, Govt. Medical College, Kottayam, Kerala, India
  • Sansho E. U. Department of General Surgery, Govt. Medical College, Kottayam, Kerala, India
  • Sandeep Varghese Department of General Surgery, Govt. Medical College, Kottayam, Kerala, India
  • Toney Jose Department of General Surgery, Govt. Medical College, Kottayam, Kerala, India

DOI:

https://doi.org/10.18203/2349-2902.isj20174163

Keywords:

Critical limb ischemia, Level of amputation, Prostaglandin E1, Ulcer healing

Abstract

Background: Diffuse peripheral arterial disease or peripheral occlusive vascular disease (POVD) involving the lower limb is a debilitating illness with high incidence of morbidity and mortality. The objective of this study was to assess the improvement of ulcer healing and improvement of the level of amputation in patients with diffuse peripheral arterial disease after administration of prostaglandin E1.

Methods: From June 2013 to November 2014, a total of 45 patients having critical limb ischaemia (Fontaine’s grade III and IV) not suitable for angioplasty and stenting or bypass procedures received different courses of Prostaglandin E1 (PGE1). 20 patients (44.44%) received 6 full courses of PGE1, 3 patients (6.66%) received 5 courses, 5 patients (11.11%) received 4 courses, 4 patients (8.8%) received 3 courses, 4 patients (8.8%) received 2 courses and 9 patients (20%) received one course. PGE1 was administered through intravenous infusion (Alprastodil 100mcg) over 10 hours a day for 5 days in one month (1course). They were followed up for 3 years till June 2017.The improvement in level of amputation, ulcer healing and complications were assessed.

Results: 14 patients (31.1%) did not require amputation of limbs/ toes, 24 patients (53.3%) have the same amputated status while 7 patients (15.6%) required higher amputation. This study justifies the role of PGE1 therapy in improving the peripheral arterial pulsations and thereby augmenting ulcer healing and improving the level of amputation.

Conclusions: After diagnosing a patient with advanced CLI where angioplasty and stenting or bypass procedures are not possible, aggressive treatment for the non-healing ulcer, amputation of gangrenous limbs or toes and starting the PGE1 therapy early not only arrest the progression of POVD but even reverses it to some extent.

Author Biography

John S. Kurien, Department of General Surgery, Govt. Medical College, Kottayam, Kerala, India

Assistant Professor,Department of General Surgery

References

Peter T, McCollum BA, Michael A, Walker MB. The choice between limb salvage and amputation: Major limb amputation for end stage peripheral vascular disease; Level selection and alternative options, 2002. Available at http://www.oandplibrary.org/alp/chap02-03.asp.

Teraa M, ConteMS, Moll FL, Verhaar MC. Critical limb ischemia: Current trends and future directions. J Am Heart Assoc. 201623;5(2):e002938.

Carter SA. The challenge and importance of defining critical limb ischemia. Vasc Med. 1997;2(2):126-31.

Silva MB, Choi JRL, Cheng C. Peripheral arterial occlusive disease. Sabiston textbook of surgery. 19th edition. Elsevier; 2012:1725-1736.

Soga Y, Iida O, Takahara M, Hirano K, Suzuki K, Kawasaki D, et al. Two-year life expectancy in patients with critical limb ischemia. JACC Cardiovasc Interv. 2014;7(12):1444-9.

Weiss T. Mechanisms of action of prostaglandin E1 in therapy of peripheral arterial occlusive diseases. Vasa. 2003;32(4):187-92.

Marchesi S, Pasqualini L, Lombardini R, Vaudo G, Lupattelli G, Pirro M, et al. Prostaglandin E1 improves endothelial function in critical limb ischemia. J Cardiovasc Pharmacol. 2003;41(2):249-53.

Stricker H, Kaiser U, Frei J, Mahler F. Acute and long-term effects of prostaglandin E1 assessed by clinical and microcirculatory parameters in critical limb ischemia: a pilot study. Int J Microcirc Clin Exp. 1996;16(2):57-63.

Creutzig A. Therapy of peripheral arterial occlusive disease with special reference to prostaglandins. Z Gesamte Inn Med. 1991;46(3):59-67.

Management of peripheral arterial disease (PAD), In: Trans- Atlantic Inter-Society Consensus (TASC), Pharmacotherapy for CLI. Inter Anglo. 2000;1 (suppl):183-98.

Bucci M, Iacobitti P, Laurora G, Cesarone MR. Analysiss of costs and results of prostaglandin (PGE1 alpha-cyclodesin) therapy of peripheral arterial diseases. Minerva Cardioangiol. 1998;46(10 suppl 1):9-15.

Occhionorelli S, Mascoli F, Vasquez G, Santini M, Navarra G, Carcoforo P. Use of PGE1 in severe ischemia of the lower extremitis. Clinical study. Minerva Cardioangiol. 1995;43(6):247-56.

Andreev A, Petkov D, Kavrakov T. An amputation alternative for the patients with critical limb ischemia. Int J Angiol. 2002;11(2)63-6.

Lukanova D, Batchvarova V, Petrov V. Clinical assessment of the effects of prostaglandin E1 in treatment of patients in III and IV stage of chronic arterial insufficiency of the extremities by the Fontaine. 18th World Congress of the International Union of Angiology, Rome, Book of abstracts; 1997.

Norgen L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR. Inter - society consensus for the management of peripheral arterial disease (TASC II). Jour Vasc Surg. 2007;45(1)S5-67.

Downloads

Published

2017-09-27

Issue

Section

Original Research Articles